2008•Naunyn-Schmiedeberg s Archives of PharmacologyRequires access

Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure

Henriette Schneider, Oliver Hüsser, Munhie Rihm, Sabine Fredersdorf, Christoph Birner, Stefan Dhein, Frank Muders, Andreas Jeron, Heinz Goegelein, G. Riegger, Andreas Luchner

Open publisher page 4 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Dofetilide, Terfenadine, Torsades de pointes, QT interval, Medicine, Heart failure, Atrial fibrillation, Cardiology

Back to paper search Browse research topics Original source

Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure — Research Paper | ScholarLens